摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-methylpiperazine-2-carboxamide | 859286-94-5

中文名称
——
中文别名
——
英文名称
1-methylpiperazine-2-carboxamide
英文别名
1-methyl-2-Piperazinecarboxamide
1-methylpiperazine-2-carboxamide化学式
CAS
859286-94-5
化学式
C6H13N3O
mdl
——
分子量
143.189
InChiKey
AMUHUGOLEGMWSS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.4
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.83
  • 拓扑面积:
    58.4
  • 氢给体数:
    2
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    1-methylpiperazine-2-carboxamide 、 N-(5-oxopentyl)-5-(thiophen-2-yl)isoxazole-3-carboxamide 在 三乙酰氧基硼氢化钠溶剂黄146 作用下, 以 甲醇 为溶剂, 反应 16.0h, 以130 mg的产率得到N-(5-(3-carbamoyl-4-methylpiperazin-1-yl)pentyl)-5-(thiophen-2-yl)isoxazole-3-carboxamide
    参考文献:
    名称:
    [EN] ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF
    [FR] COMPOSÉS D'ISOXAZOLE CARBOXAMIDE ET LEURS UTILISATIONS
    摘要:
    提供了一个化合物的化学式(I)或其药用盐,已被证明对治疗听力损失或平衡障碍有用:化学式(I),其中R1和Y的定义如下。
    公开号:
    WO2020058913A1
  • 作为产物:
    描述:
    4-benzyl-1-methyl-2-piperazinecarbonitrile 在 palladium 10% on activated carbon 、 potassium tert-butylate氢气 作用下, 以 甲醇叔丁醇 为溶剂, 10.0~30.0 ℃ 、344.75 kPa 条件下, 反应 88.0h, 生成 1-methylpiperazine-2-carboxamide
    参考文献:
    名称:
    [EN] ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF
    [FR] COMPOSÉS D'ISOXAZOLE CARBOXAMIDE ET LEURS UTILISATIONS
    摘要:
    提供了一个化合物的化学式(I)或其药用盐,已被证明对治疗听力损失或平衡障碍有用:化学式(I),其中R1和Y的定义如下。
    公开号:
    WO2020058913A1
点击查看最新优质反应信息

文献信息

  • PYRAZOLE DERIVATIVES
    申请人:DAIICHI PHARMACEUTICAL CO., LTD.
    公开号:EP1762568A1
    公开(公告)日:2007-03-14
    A compound represented by formula (I): (wherein Ar1 represents a phenyl group which may have 1 to 3 substituents, or a non-substituted 5- or 6-membered aromatic heterocyclic group; Ar2 represents (i) a non-substituted phenyl group, (ii) a phenyl group which has been substituted by a lower alkyl group having 1 to 3 groups or atoms selected from among a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom, or (iii) a 5- or 6-membered nitrogen-containing aromatic heterocyclic group which has been substituted by 1 to 3 groups or atoms selected from among a lower alkyl group, a lower alkynyl group, a lower alkanoyl group, a carbamoyl group, a cyano group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom; and X represents a group represented by formula (II): (wherein the ring structure represents a 4- to 7-membered heterocyclic group which may have, in addition to the nitrogen atom shown in formula (II), one heteroatom selected from among nitrogen, oxygen, and sulfur, and which may be substituted by 1 to 4 groups or atoms selected from among a lower alkyl group, a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, an oxo group, a lower alkanoyl group, a lower alkylsulfonyl group, and a halogen atom)), a salt thereof, a solvate of the compound or the salt, and a drug.
    由式(I)表示的化合物: (其中Ar1代表可能具有1到3个取代基的苯基,或者是非取代的5-或6-成员芳香杂环基团;Ar2代表(i)非取代的苯基团,(ii)已被1到3个来自羰胺基、氨基、羟基、低烷氧基和卤原子的群或原子取代的较低烷基基团取代的苯基团,或者(iii)已被1到3个来自低烷基基团、低炔基基团、低烷酰基团、羰胺基、氰基、氨基、羟基、低烷氧基和卤原子的群或原子取代的5-或6-成员含氮芳香杂环基团;X代表由式(II)表示的基团: (其中环结构表示可能具有除了式(II)中显示的氮原子之外,从氮、氧和硫中选择的一个杂原子的4-到7-成员杂环基团,并且可能被1到4个来自低烷基基团、羰胺基、氨基、羟基、低烷氧基、氧基、低烷酰基团、低烷基磺酰基团和卤原子的群或原子取代)),其盐,该化合物或其盐的溶剂化合物,以及药物。
  • Heterocyclic Compound
    申请人:HASHIMOTO Kentaro
    公开号:US20110034469A1
    公开(公告)日:2011-02-10
    The present invention provides a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof. The compound of the present invention shows a strong IAP antagonistic activity.
    本发明提供了一种由下式表示的化合物 其中,每个符号如说明书中所定义,或其盐。本发明的化合物表现出强烈的IAP拮抗活性。
  • SUBSTITUTED PIPERIDINES AS SODIUM CHANNEL BLOCKERS
    申请人:Purdue Pharma L.P.
    公开号:US20150057300A1
    公开(公告)日:2015-02-26
    The present disclosure provides substituted piperidines or pyrrolidines having Formula IA: and the pharmaceutically acceptable salts and solvates thereof, wherein R 1 , R 2a , R 2b , R 6 , A, X, m and n are defined as set forth in the specification. In certain embodiments, Compounds of the present disclosure are useful for treating pain. The present disclosure is also directed to the use of Compounds of the present disclosure to treat a disorder responsive to blockade of one or more sodium channels.
    本公开提供具有公式IA的取代哌啶或吡咯烷: 及其药用可接受的盐和溶剂化物,其中R1,R2a,R2b,R6,A,X,m和n按说明书定义。在某些实施方式中,本公开的化合物可用于治疗疼痛。本公开还涉及使用本公开的化合物来治疗对阻断一个或多个钠通道有反应的疾病。
  • PYRIDINES AND PYRIMIDINES AND USE THEREOF
    申请人:Purdue Pharma L.P.
    公开号:US20170008882A1
    公开(公告)日:2017-01-12
    The present disclosure provides pyridines and pyrimidines of Formula I and pharmaceutically acceptable salts and solvates thereof: wherein A, G, W 1 , W 2 , W 3 , and R 5 are defined as set forth in the specification. The present disclosure also provides uses of the compounds of Formula I and pharmaceutically acceptable salts and solvates thereof. In certain embodiments, Compounds of the present disclosure are useful for treating pain. In another embodiment, Compounds of the present disclosure are useful for treating a disorder responsive to blockade of sodium channels, or alleviating symptoms of the disorder.
    本公开提供了Formula I的吡啶和嘧啶以及其药用可接受的盐和溶剂化合物:其中A、G、W1、W2、W3和R5如规范中所述。本公开还提供了Formula I化合物及其药用可接受的盐和溶剂的用途。在某些实施例中,本公开的化合物对治疗疼痛有用。在另一实施例中,本公开的化合物对治疗对钠通道阻滞有反应的疾病,或缓解该疾病的症状有用。
  • INDOLE DERIVATIVES AND USE THEREOF
    申请人:Purdue Pharma L.P.
    公开号:US20150284383A1
    公开(公告)日:2015-10-08
    The Invention provides indole derivatives of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R 1e , R 1f , A, X, Y, Z, and W 4 are defined as set forth in the specification. The Invention also provides the use of compounds of Formula I and the pharmaceutically acceptable salts and solvates thereof to treat pain. In certain embodiments, the Compounds of the Invention are effective in treating a disorder responsive to blockade of one or more sodium channels.
    本发明提供了公式I的吲哚衍生物及其药学上可接受的盐和溶剂化合物,其中R1e、R1f、A、X、Y、Z和W4如规范中所述。本发明还提供了利用公式I的化合物及其药学上可接受的盐和溶剂来治疗疼痛。在某些实施例中,本发明的化合物对于治疗对一个或多个钠通道阻滞有响应的疾病是有效的。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物